For example, the TβRI (TGF beta receptor 1) kinase inhibitor galunisertib has been evaluated in two phase II clinical trials for hepatocellular carcinoma (HCC), and treatment with galunisertib showed improvement in overall survival in both clinical phase II trials [100]. This evidence concerns the gene TGFBR1 and hepatocellular carcinoma.